Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Josephine Anne Lucero, Maria Perusini, Aniket Bankar, Marta Davidson, Guillaume Richard-Carpentier, Aaron Schimmer, Andre Schuh, Dawn Maze, Karen W.L. Yee, Mark Minden, Steven Chan, Jose-Mario Capo-Chichi, Vikas Gupta, Hassan Sibai, Anne Tierens, Dennis Kim

Blood (2025) 146 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2025-7051

Published: 2025

Journal Articles

Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax

Aarya Murali, Zahra AlHaj Issa, Cristiano Machado De Freitas, Akhil Rajendra, Marta Davidson, Aniket Bankar, Hassan Sibai, Maria Perusini, Steven Chan, Aaron Schimmer, Mark Minden, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Dawn Maze, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 3508.

https://doi.org/10.1182/blood-2025-3508

Published: 2025

Journal Articles

The mitochondrial protease YME1L regulates type 1 interferon signaling via the cgas-sting pathway in AML

Yihe Zhang, Geethu Thomas, Rose Hurren, Yongran Yan, Dakai Ling, Marcela Gronda, Andrea Arruda, Mark Minden, Aaron Schimmer

Blood (2025) 146 (Supplement 1): 6765.

https://doi.org/10.1182/blood-2025-6765

Published: 2025

Journal Articles

FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML

Akhil Rajendra, Dawn Maze, Aniket Bankar, Steven Chan, Marta Davidson, Vikas Gupta, Mark Minden, Maria Perusini, Guillaume Richard-Carpentier, Aaron Schimmer, Andre Schuh, Elliot Smith, Karen W.L. Yee, Hassan Sibai

Blood (2025) 146 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2025-1672

Published: 2025

Journal Articles

PKM2 modulation regulates leukemia cell survival.

Nikolina Vrdoljak, Paul Spagnuolo, Mark Minden, Ekaterina Parfenova, Alessia Roma, Drake Mosca

Blood (2025) 146 (Supplement 1): 3240.

https://doi.org/10.1182/blood-2025-3240

Published: 2025

Journal Articles

Real-world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin (GO) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and favorable or intermediate risk cytogenetics

Elizabeth Herrity, Dawn Maze, Marta Davidson, Aniket Bankar, Maria Perusini, Hassan Sibai, Steven Chan, Aaron Schimmer, Mark Minden, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 5240.

https://doi.org/10.1182/blood-2025-5240

Published: 2025

Journal Articles

Prognostic impact of molecular genetic and cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with azacitidine and venetoclax: A real-world cohort study

Cristiano Machado De Freitas, Aarya Murali, Zahra AlHaj Issa, Aniket Bankar, Hassan Sibai, Maria Perusini, Aaron Schimmer, Mark Minden, Steven Chan, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Dawn Maze, Marta Davidson, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 4776.

https://doi.org/10.1182/blood-2025-4776

Published: 2025

Journal Articles

Comparable remission rates in therapy-related and myelodysplasia-related Acute Myeloid Leukemia (AML) versus de novo AML treated with azacitidine and venetoclax: A contemporary real-world study.

Zahra AlHaj Issa, Cristiano Machado De Freitas, Aarya Murali, Akhil Rajendra, Dawn Maze, Aniket Banker, Steven Chan, Marta Davidson, Aaron Schimmer, Andre Schuh, Hassan Sibai, Karen W.L. Yee, Mark Minden, Vikas Gupta, Maria Perusini, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2025-3390

Published: 2025

Journal Articles

Extramedullary disease in AML: A high-risk feature beyond ELN 2022 classification

Yael Morgenstern, Claire Andrews, Eshetu Atenafu, Steven Chan, Vikas Gupta, Mark Minden, Dawn Maze, Aaron Schimmer, Andre Schuh, Karen W.L. Yee, Hassan Sibai

Blood (2025) 146 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2025-3388

Published: 2025

Journal Articles

Emergence of new somatic mutations in CML patients optimally responding to tyrosine kinase inhibitor therapy: Proposal of long-term genomic monitoring

Yael Morgenstern, Gopila Gupta, Flavia Patino, Maria Perusini, Daniela Zackova, Ivana Jeziskova, Anezka Kvetkova, Tomas Jurcek, Azin Keshavarz, Danielle Pyne, Oyeronke Ayansola, Amirthagowri Ambalavanan, Jiri Mayer, Andrea Arruda, Mark Minden, Jessie Medeiros, Sagi Abelson, Dennis Kim

Blood (2025) 146 (Supplement 1): 3767.

https://doi.org/10.1182/blood-2025-3767

Published: 2025

Journal Articles

Mixed phenotype acute leukemia: Clinical characteristics and real-world outcomes

Ana Patiño, Hong Chang, Mark Turingan, Aniket Bankar, Jonathan Wei, Marta Davidson, Guillaume Richard-Carpentier, Mark Minden, Andre Schuh, Karen W.L. Yee, Vikas Gupta, Dawn Maze, Steven Chan, Aaron Schimmer, Claire Andrews, Hassan Sibai, Maria Perusini

Blood (2025) 146 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2025-3330

Published: 2025

Journal Articles

Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate Acute Myeloid Leukemia cells

Ekaterina Parfenova, Nikolina Vrdoljak, Drake Mosca, Juan Aristizabal-Henao, Michael Kiebish, Mark Minden, Paul Spagnuolo

Blood (2025) 146 (Supplement 1): 5281.

https://doi.org/10.1182/blood-2025-5281

Published: 2025

Journal Articles

KMT2E-ASNS: a novel relapse-specific fusion gene in early T-cell precursor acute lymphoblastic leukemia

Fida Khater, Mathieu Lajoie, Sylvie Langlois, Jasmine Healy, Sonia Cellot, Chantal Richer, Patrick Beaulieu, Pascal St-Onge, Virginie Saillour, Mark Minden, Monia Marzouki, Maja Krajinovic, Henrique Bittencourt, Daniel Sinnett

Blood (2017) 129 (12): 1729–1732.

https://doi.org/10.1182/blood-2016-10-744219

Published: 2017

Includes: Supplemental data

Journal Articles

PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia

Stephanie Tung, Yonghong Shi, Karry Wong, Fang Zhu, Reg Gorczynski, Robert C. Laister, Mark Minden, Anne-Kareen Blechert, Yvonne Genzel, Udo Reichl, David E. Spaner

Blood (2013) 122 (6): 969–980.

https://doi.org/10.1182/blood-2013-03-489468

Published: 2013

Includes: Supplemental data

Journal Articles

An Upstream Insulator Element Regulates DLK1 Imprinting in AML

Haytham Khoury, MD, Fernando Suarez-Saiz, Samantha Wu, Serban San-Marina, Mark Minden

Blood (2008) 112 (11): 202.

https://doi.org/10.1182/blood.V112.11.202.202

Published: 2008

Journal Articles

Distinct Proteomic Signaling Networks Stratify Responses to Ara-C Based Induction Therapy in Patients with Acute Myeloid Leukemia (AML)

Mark Minden, David Rosen, Santosh Putta, Aileen Cohen, Helen Francis-Lang, Todd Covey, John Woronicz, David Soper, Brian Long, James Cordeiro, Lootsie Panganiban-Lustan, Steve Banville, Urte Gayko, Alessandra Cesano, Wendy Fantl

Blood (2008) 112 (11): 2549.

https://doi.org/10.1182/blood.V112.11.2549.2549

Published: 2008

Journal Articles

Treatment of Adult T-ALL with a Pediatric Asparaginase-Intensive Protocol Results in Survival Benefit When Compared to Other Adult Based Protocols

Murtadha K. Al-Khabori, BSc, MD, FRCPC, Mark Minden, Vikas Gupta, Aaron D. Schimmer, Andre C. Schuh, Karen WL Yee, Wei Xu, Joseph M. Brandwein

Blood (2008) 112 (11): 3956.

https://doi.org/10.1182/blood.V112.11.3956.3956

Published: 2008

Journal Articles

Outcome of Patients Age 60 and Over with Acute Lymphoblastic Leukemia (ALL) Treated with a Modified Pediatric Protocol

Susan Kao, MD, Wei Xu, PhD, Vikas Gupta, MD, MRCP, MRCPath, Mark Minden, Andre Schuh, MD, Aaron D. Schimmer, Karen WL Yee, Joseph Brandwein, MD, FRCPC

Blood (2008) 112 (11): 3962.

https://doi.org/10.1182/blood.V112.11.3962.3962

Published: 2008

Journal Articles

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

Guillermo Garcia-Manero, Sarit Assouline, Jorge Cortes, Zeev Estrov, Hagop Kantarjian, Hui Yang, Willie M. Newsome, Wilson H. Miller, Jr, Caroline Rousseau, Ann Kalita, Claire Bonfils, Marja Dubay, Tracy-Ann Patterson, Zuomei Li, Jeffrey M. Besterman, Gregory Reid, Eric Laille, Robert E. Martell, Mark Minden

Blood (2008) 112 (4): 981–989.

https://doi.org/10.1182/blood-2007-10-115873

Published: 2008

Includes: Supplemental data

Journal Articles

Impact of Myeloablative Versus Reduced Intensity Conditioning Regimens on Early Lymphocyte Recovery and Its Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients with Hematologic Malignancies.

Dong Hwan (Dennis) Kim, MD, PhD, Gizelle Popradi, MD, John Kuruvilla, MD, Vikas Gupta, MD, Mark Minden, MD, PhD, Jeffrey H. Lipton, MD, PhD, Hans A. Messner, MD, PhD

Blood (2007) 110 (11): 5039.

https://doi.org/10.1182/blood.V110.11.5039.5039

Published: 2007

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax

The mitochondrial protease YME1L regulates type 1 interferon signaling via the cgas-sting pathway in AML

FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML

PKM2 modulation regulates leukemia cell survival.

Real-world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin (GO) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and favorable or intermediate risk cytogenetics

Prognostic impact of molecular genetic and cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with azacitidine and venetoclax: A real-world cohort study

Comparable remission rates in therapy-related and myelodysplasia-related Acute Myeloid Leukemia (AML) versus de novo AML treated with azacitidine and venetoclax: A contemporary real-world study.

Extramedullary disease in AML: A high-risk feature beyond ELN 2022 classification

Emergence of new somatic mutations in CML patients optimally responding to tyrosine kinase inhibitor therapy: Proposal of long-term genomic monitoring

Mixed phenotype acute leukemia: Clinical characteristics and real-world outcomes

Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate Acute Myeloid Leukemia cells

KMT2E-ASNS: a novel relapse-specific fusion gene in early T-cell precursor acute lymphoblastic leukemia

PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia

An Upstream Insulator Element Regulates DLK1 Imprinting in AML

Distinct Proteomic Signaling Networks Stratify Responses to Ara-C Based Induction Therapy in Patients with Acute Myeloid Leukemia (AML)

Treatment of Adult T-ALL with a Pediatric Asparaginase-Intensive Protocol Results in Survival Benefit When Compared to Other Adult Based Protocols

Outcome of Patients Age 60 and Over with Acute Lymphoblastic Leukemia (ALL) Treated with a Modified Pediatric Protocol

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

Impact of Myeloablative Versus Reduced Intensity Conditioning Regimens on Early Lymphocyte Recovery and Its Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients with Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only